DrugPatentWatch Database Preview

BOEHRINGER INGELHEIM Company Profile

« Back to Dashboard

What is the competitive landscape for BOEHRINGER INGELHEIM, and what generic alternatives to BOEHRINGER INGELHEIM drugs are available?

BOEHRINGER INGELHEIM has forty-eight approved drugs.

There are eighty-one US patents protecting BOEHRINGER INGELHEIM drugs.

There are two thousand two hundred and forty-four patent family members on BOEHRINGER INGELHEIM drugs in sixty-four countries and two hundred and twenty supplementary protection certificates in nineteen countries.

Summary for BOEHRINGER INGELHEIM

International Patents:	2244
US Patents:	81
Tradenames:	40
Ingredients:	30
NDAs:	48
Patent Litigation for BOEHRINGER INGELHEIM:	See patent lawsuits for BOEHRINGER INGELHEIM
PTAB Cases with BOEHRINGER INGELHEIM as petitioner:	See PTAB cases with BOEHRINGER INGELHEIM as petitioner

Drugs and US Patents for BOEHRINGER INGELHEIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-002	Jan 27, 2020		RX	Yes	No	10,406,172		Y
Boehringer Ingelheim	TRIJARDY XR	empagliflozin; linagliptin; metformin hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212614-004	Jan 27, 2020		RX	Yes	Yes	10,596,120		Y
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-001	Sep 24, 2014		RX	Yes	Yes
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-003	Jul 1, 1997	AB	RX	Yes	No
Boehringer Ingelheim	GILOTRIF	afatinib dimaleate	TABLET;ORAL	201292-003	Jul 12, 2013		RX	Yes	Yes
Boehringer Ingelheim	JARDIANCE	empagliflozin	TABLET;ORAL	204629-001	Aug 1, 2014		RX	Yes	No	7,713,938		Y	Y

Expired US Patents for BOEHRINGER INGELHEIM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Boehringer Ingelheim	SPIRIVA RESPIMAT	tiotropium bromide	SPRAY, METERED;INHALATION	021936-002	Sep 15, 2015	5,964,416*PED
Boehringer Ingelheim	MICARDIS HCT	hydrochlorothiazide; telmisartan	TABLET;ORAL	021162-001	Nov 17, 2000	5,591,762
Boehringer Ingelheim	MIRAPEX	pramipexole dihydrochloride	TABLET;ORAL	020667-002	Jul 1, 1997	6,001,861
Boehringer Ingelheim	STRIVERDI RESPIMAT	olodaterol hydrochloride	SPRAY, METERED;INHALATION	203108-001	Jul 31, 2014	6,846,413
Boehringer Ingelheim	COMBIVENT RESPIMAT	albuterol sulfate; ipratropium bromide	SPRAY, METERED;INHALATION	021747-001	Oct 7, 2011	6,453,795
Boehringer Ingelheim	CATAPRES-TTS-1	clonidine	SYSTEM;TRANSDERMAL	018891-001	Oct 10, 1984	3,454,701
Boehringer Ingelheim	ATROVENT	ipratropium bromide	SPRAY, METERED;NASAL	020394-001	Oct 20, 1995	4,385,048

Paragraph IV (Patent) Challenges for BOEHRINGER INGELHEIM drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	2.5 mg/500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg		2015-05-04
	Tablets	80 mg/12.5 mg and 40 mg/12.5 mg		2008-12-31
	Extended-release Capsules	25 mg and 200 mg		2007-02-01
	Tablets	0.125 mg, 0.5 mg, 1 mg and 1.5 mg		2005-06-24
	Capsules	eq. to 75 mg base and 150 mg base		2014-10-20
	Tablets	0.75 mg		2008-07-31
	Inhalation Powder Capsules	18 mcg		2018-05-11
	Tablets	5 mg/500 mg5 mg/1000 mg12.5 mg/500 mg12.5 mg/1000 mg		2018-08-01
	Extended-release Tablets	0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg		2010-06-01
	Extended-release Tablets	5 mg/1000 mg10 mg/1000 mg12.5 mg/1000 mg25 mg/1000 mg		2018-08-01
	Tablets	20 mg, 30 mg and 40 mg		2017-07-12
	Tablets	10 mg and 25 mg		2018-08-01
	Tablets	20 mg, 40 mg and 80 mg		2006-12-26
	Tablets	80 mg/25 mg		2009-02-27
	Capsules	100 mg and 150 mg		2018-10-15
	Tablets	0.25 mg		2005-05-27
	Capsules	eq. to 110 mg base		2015-12-15
	Oral Suspension	7.5 mg/5 mL		2009-12-17
	Extended-releaseTablets	2.5 mg/1000 mg 5 mg/1000 mg		2018-03-28
	Tablets	5 mg		2015-05-04
	Extended-release Tablets	2.25 mg and 3.75 mg		2011-07-26
	Extended-release Tablets	400 mg		2013-06-21
	Tablets	10 mg/5 mg and 25 mg/5 mg		2018-08-01

International Patents for BOEHRINGER INGELHEIM Drugs

Country	Patent Number	Estimated Expiration
Peru	01072001
Canada	2432428
Spain	2616606
South Korea	20030051706
Colombia	5700803
Mexico	PA02009750
Canada	2373094

Supplementary Protection Certificates for BOEHRINGER INGELHEIM Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1562603	SPC/GB14/023	United Kingdom		PRODUCT NAME: OLODATEROL OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF; REGISTERED: MT MA 211/00401 20130918; UK PL 14598/0093 20131010
1345910	92370	Luxembourg		PRODUCT NAME: AFATINIB,LES TAUTOMERES,LES STEREOISOMERES ET LES SELS DE CELUI-CI,DES SELS PHYSIOLOGIQUEMENT ACCEPTABLES DE CELUI-CI AVEC DES ACIDES OU BASES ORGANIQUES OU INORGANIQUES,DE PREFERENCE UN SEL MALEATE DE CELUI-CI,ET PLUS DE PREFERENCE UN SEL DIMALEATE DE CELUI-CI
1507558	2012/018	Ireland		PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705
1730131	C01730131/02	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND METFORMINHYDROCHLORID; REGISTRATION NO/DATE: SWISSMEDIC 65570 12.11.2015
2187879	20/2017	Austria		PRODUCT NAME: KOMBINATION VON EMPAGLIFLOZIN UND LINAGLIPTIN ODER PHARMAZEUTISCH VERTRETBARE SALZE; REGISTRATION NO/DATE: EU/1/16/1146 (MITTEILUNG) 20161115
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
1730131	C01730131/03	Switzerland		PRODUCT NAME: EMPAGLIFLOZIN UND LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66132 29.03.2017

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Boehringer Ingelheim